8-K: Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-115, Shifts Focus to Obesity Portfolio

Vivani Medical reports positive preclinical results for its NPM-115 exenatide implant, showing weight loss comparable to Ozempic/Wegovy, and discloses NPM-139 as a semaglutide implant, shifting its focus to obesity treatments.

Summary

• Vivani Medical has announced positive preclinical data for its NPM-115 implant, designed for chronic weight management, showing weight loss results comparable to semaglutide injections (Ozempic/Wegovy) in mice.
• The company also disclosed that NPM-139, another implant in development, uses semaglutide as its active ingredient and has the potential for once-yearly dosing.
• This strategic shift prioritizes the company's obesity implants due to the potential of high-dose GLP-1 products to improve health outcomes for obese and overweight patients.
• NPM-115 is a miniature, twice-yearly exenatide implant, while NPM-139 is a once-yearly semaglutide implant.
• In a study with obese mice, NPM-115 resulted in approximately 20% weight loss after 28 days, similar to the weight loss observed with semaglutide injections.
• A separate study with healthy rats showed that a single administration of the company's exenatide implant, NPM-119, resulted in body weights approximately 25% lower than a control group after 15 weeks.
• The company believes its NanoPortal implant technology can improve medication adherence and tolerability, potentially transforming GLP-1 therapy adoption.
• Medication non-adherence is a significant issue, affecting approximately 50% of patients and contributing to over $500 billion in annual avoidable healthcare costs in the U.S.

Sentiment

Score: 7

Explanation: The document presents positive preclinical data and a strategic shift towards a high-demand market, but also acknowledges existing challenges and risks, resulting in a moderately positive sentiment.

Positives

• The preclinical data for NPM-115 shows promising weight loss results, comparable to existing treatments like Ozempic/Wegovy.
• The development of NPM-139 as a once-yearly semaglutide implant offers a potentially more convenient treatment option.
• The company's strategic shift to prioritize obesity treatments aligns with the growing market demand for effective weight management solutions.
• The NanoPortal technology has the potential to significantly improve medication adherence, addressing a major challenge in chronic disease management.
• The company has a clear plan to advance NPM-115 and NPM-119 towards clinical trials in 2024.

Negatives

• The company's NPM-119 program is currently on clinical hold due to insufficient Chemistry, Manufacturing and Controls (CMC) information requested by the FDA.
• The company has a history of losses and will need to raise additional capital to fund its operations.
• The company is dependent on third parties for some aspects of product manufacturing, research, and testing.
• The company's products are still investigational and have not been approved by any regulatory authority for any use.

Risks

• The company may fail to complete required pre-clinical activities for NPM-115, NPM-119, or other products.
• The company's products may not demonstrate safety or efficacy in clinical trials.
• There may be delays in regulatory approval or changes in the regulatory framework.
• The company may fail to secure marketing approvals for its products.
• The company may fail to raise additional required funding.
• More efficient competitors or more effective competing treatments may emerge.
• The company may be involved in disputes surrounding the use of its intellectual property.
• The company may not be able to attract and retain key employees and qualified personnel.
• Earlier study results may not be predictive of later-stage study outcomes.

Future Outlook

Vivani plans to submit an Investigational New Drug application for NPM-115 in 2024 to support the initiation of a first-in-human trial for chronic weight management. The company also expects to submit requested CMC information to the FDA in the first half of 2024 to resolve the clinical hold on NPM-119.

Management Comments

• Adam Mendelsohn, Ph.D., Vivani President and Chief Executive Officer, stated that the company is prioritizing the development of GLP-1 implants for obesity and chronic weight management due to the tremendous medical need and market demand.
• Dr. Mendelsohn also believes that the company's NanoPortal implant technology has the potential to transform and advance the adoption of GLP-1 therapy by improving medication adherence and tolerability.

Industry Context

This announcement comes amid a growing interest in GLP-1 therapies for weight management, with companies like Novo Nordisk experiencing significant success with drugs like Ozempic and Wegovy. Vivani's focus on long-term implantable solutions addresses the issue of medication adherence, a key challenge in the broader market.

Comparison to Industry Standards

• The preclinical weight loss results of NPM-115 are compared to semaglutide injections (Ozempic/Wegovy), which are established treatments in the obesity market.
• The document references a study showing that adherence to semaglutide is only 40% after one year, highlighting the potential advantage of Vivani's implant technology.
• The document mentions Intarcia's ITCA 650, a previous exenatide implant, as a relevant value analog, noting its challenges with regulatory approval and device technology.
• The document cites JP Morgan analyst Richard Vosser's estimate that the GLP-1 market will reach $71 billion by 2032, indicating the significant market potential for Vivani's products.

Stakeholder Impact

• Shareholders may view the positive preclinical data and strategic shift as positive developments.
• Employees may be impacted by the shift in focus and the need to address the clinical hold on NPM-119.
• Customers (patients) may benefit from the development of new, more convenient treatment options for obesity and type 2 diabetes.
• Suppliers and creditors may be impacted by the company's financial performance and need for additional capital.

Next Steps

• Vivani plans to submit an Investigational New Drug application for NPM-115 to support a first-in-human trial.
• The company will submit requested CMC information to the FDA to resolve the clinical hold on NPM-119.
• Dr. Mendelsohn will present study results at the TIDES USA 2024 conference in Boston on May 17.

Key Dates

Keywords

GLP-1, exenatide, semaglutide, obesity, weight management, type 2 diabetes, implant, NanoPortal, medication adherence, preclinical data, clinical trials